The US Federal Trade Commission said Monday it has approved of the proposed merger between pharmaceutical companies VersaPharm and Akorn, but has imposed conditions on the transaction.

Akorn plans to acquire VersaPharm in a $440 million deal first announced in May; the deal will expand Akorn’s drug marketing and development operations.

The …read more

Source: Global Competition Law Blogs